Issuance of warrants

Faron Pharmaceuticals Oy

30/04/2026 07:00

Faron Pharmaceuticals Ltd | Company announcement | April 30, 2026 at 09:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 321,523 additional warrants over ordinary shares in the Company (“Warrants”), following the the amortisation of the first and second tranche convertible bonds to Heights Capital Management, Inc.at EUR 0.4516 announced on 13 April 2026.

The subscription price of all of the Warrants held by IPF is reset to EUR 0.4516 (“Subscription Price”). As described in the Warrant Terms and Conditions announcement of 8 April 2024, in the event of any future share issue at a price lower than the Subscription Price, the Subscription Price of the Warrants will be adjusted to that lower subsequent price.

Following this issues, IPF will have an interest in 3,641,467 Warrants, representing approximately 1.83% of the issued share capital in the Company. Each Warrant entitles its holder to subscribe for one new share in the Company. The Warrants may be exercised for a period of seven years from the original date of issue.

For more information, please contact:

IR Partners, Finland
(Media)

 Kare Laukkanen

 +358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
FINN Partners, US
(Media) 
 Alyssa Paldo 
+1 847 791-8085 
alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
 Sandy Jamieson, Jo Turner
+44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
 Juha Karttunen
 Jukka Järvelä
+358 (0)40 555 4727
 +358 (0)50 553 8990

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company’s lead asset, bexmarilimab, is a novel macrophage-guiding immunotherapy being investigated in multiple oncology settings. Further information is available at www.faron.com.